Generex Biotechnology Corp. (fka GNBTQ)

[WeeZuhl]

Still pumpy, but better.

The spin-out will be accomplished by the issuance of one or more dividends of NuGenerex Immuno-Oncology stock to Generex stockholders. The record dates in respect of such dividends are yet to be determined and will be announced in due course. The stock dividends will enable Generex stockholders to directly participate in the promising future of NuGenerex Immuno-Oncology as well as create a large shareholder base with the potential for substantial liquidity on an immediate basis. That liquidity will be further enhanced should NuGenerex Immuno-Oncology be successful in attaining a national stock exchange listing, and should provide NuGenerex Immuno-Oncology with ready access to the capital markets to finance its on-going clinical and regulatory initiatives.

Seems like stock dividends is the only thing that gets this stock moving, so why not go back to the well? AE37, and more generally Ii-key activation peptide, are REAL. Ii-key is a very intriguing immunomodulator with far-ranging potential. This, along with buccal absorption I.P., are the true assets of Generex, and they have languished far too long while the company has aimlessly pursued scores of other fly-by-night opportunities that never work out. I'm glad to see Ii-key get spun off, and I hope buccal absorption does, too. Let's see more focus the real stuff and less focus on the fluffy nonsense.